Marker Therapeutics (MRKR) Operating Expenses (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Operating Expenses data on file, last reported at $4.1 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $4.1 million, down 17.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.6 million (down 17.6% YoY), and the FY2025 annual result was $16.4 million, down 7.18% from the prior year.
• Operating Expenses grew to $4.1 million in Q1 2026 per MRKR's latest filing, from $3.0 million in the prior quarter.
• Over five years, Operating Expenses peaked at $10.8 million in Q1 2022 and troughed at $3.0 million in Q4 2025.
• A 5-year average of $4.9 million and a median of $4.3 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses sank 65.49% in 2022, then soared 53.05% in 2024.
• A 5-year view of Operating Expenses shows it stood at $3.8 million in 2022, then gained by 5.17% to $4.0 million in 2023, then soared by 53.05% to $6.1 million in 2024, then plunged by 51.13% to $3.0 million in 2025, then surged by 36.32% to $4.1 million in 2026.
• Business Quant data shows MRKR's Operating Expenses at $4.1 million in Q1 2026, $3.0 million in Q4 2025, and $3.4 million in Q3 2025.